Clinical trials: Affective Disorders, Psychotic
Severe Mental Disorder, Schizophrenia
Community-based Mental Health Care for People With Severe and Enduring Mental Ill Health (RECOVER-E) Croatia
To contribute to improving the level of functioning and quality of life and mental health outcomes for people with severe and enduring mental ill health (SMI) (schizophrenia, bipolar disorder, depression) by adapting and up…
- Conditions
- Severe Mental Disorder, Schizophrenia, Bipolar Disorder, Severe Depression
- Trial name
- RECOVER-E (NCT03862209)
- Testing
- Community mental health team
- Where
- Croatia
- Volunteers
- 200 people
- Sponsor
- Klinički Bolnički Centar Zagreb
Schizophrenia, Bipolar Disorder
Person-Centered Versus Measurement-Based Care in Mental Health
Fifteen minutes is the typical length of an outpatient medication management appointment for people with serious mental health conditions.
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depression
- Trial name
- PCORI-SDM (NCT02507349)
- Testing
- Person-Centered Care, Measurement-Based Care
- Where
- 2 sites in United States
- Volunteers
- 2,443 people
- Sponsor
- University of Pittsburgh
Schizophrenia and Related Disorders, Bipolar Disorder
A Register Study of Effects Following Local Variation in Rates of Involuntary Care
Involuntary mental health care is permitted because it is believed to make people with severe mental disorders (SMD) better and prevent them from getting worse or even dying In this study we will investigate whether low levels of…
- Trial name
- NCT04655287
- Volunteers
- 21,759 people
- Sponsor
- University Hospital, Akershus
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizo Affective Disorder
D-serine Augmentation of Neuroplasticity
Schizophrenia is a major public health problem associated with cognitive deficits, such as short and long term memory, executive functioning, attention and speed of processing that are amongst the strongest predictors of impaired…
- Trial name
- NCT03711500
- Testing
- D-serine
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes
This randomized clinical trial (RCT) of 300 persons with serious mental illness (SMI) and medical comorbidity will evaluate outcomes for n=100 in a Community Based Health Home alone (CBHH), compared to n=100 also receiving…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depression
- Trial name
- NCT02188732
- Testing
- CBHH+AT, CBHH+SMT, CBHH
- Where
- 2 sites in United States
- Volunteers
- 301 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Bipolar Disorder
Physician Survey on Monitoring of Patients Treated With Quetiapine
A physician survey to document receipt of metabolic educational materials and assess behavior of physicians in following messages communicated through the educational materials
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT01795326
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Chronic Pain, Schizophrenia
CBT-CP for Veterans With SMI
Chronic musculoskeletal pain has a highly negative impact on Veterans, especially those with serious mental illness (SMI). Chronic musculoskeletal pain leads to poorer mental and physical health-related functioning, representing…
- Conditions
- Chronic Pain, Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- CP-SMI (NCT06758414)
- Testing
- Cognitive Behavioral Therapy for Chronic Pain (CBT-CP), Health & Wellness (H&W)
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- VA Office of Research and Development
Schizophenia Disorder, Schizoaffective Disorder
Exercise and Olanzapine-samidorphan
This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic…
- Conditions
- Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
- Trial name
- NCT06740890
- Testing
- Olanzapine-samidorphan + exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenic Disorders, Schizoaffective Disorders
Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)
The aim is to evaluate the effectiveness of an intervention based on a program of physical activity and diet coordinated between primary care teams (PCT) and Mental Health Centres (MHC) to modify the weekly physical activity (PA)…
- Conditions
- Schizophrenic Disorders, Schizoaffective Disorders, Bipolar Disorders
- Trial name
- CapiCor (NCT01729650)
- Testing
- Physical and diet educational group
- Where
- Spain
- Volunteers
- 332 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Affective Disorders, Psychotic, Depressive Disorder
Treatment of Psychotic Major Depression With Mifepristone
The purpose of this research study is to see how certain hormones cause changes in mood and thinking in some depressed patients and to determine the effectiveness of mifepristone in treating some forms of depression.
- Trial name
- NCT00867360
- Testing
- Mifepristone (RU-486)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Schizophrenia, Treatment Resistant Depression
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
- Conditions
- Schizophrenia, Treatment Resistant Depression, Aging, Premature
- Trial name
- NCT05838560
- Testing
- Dasatinib, quercetin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder and Irritability
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability
The purpose of this study is to explore the effects of fixed-dosed brexpiprazole adjunctive treatment in subjects with Major Depressive Disorder with irritability
- Trial name
- NCT02212613
- Testing
- Brexpiprazole
- Where
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Patient Treated With Lithium, With Bipolar or Schizo-affective Disorder, Hospitalized in a Psychiatric Ward
Validation of the French Version of the Lithium Knowledge Test (LKT)
Lithium is a drug used to treat several psychiatric illnesses. This medication requires particular vigilance because it has a narrow therapeutic margin: the dose necessary to obtain an effective treatment is close to the toxic…
- Trial name
- LKT (NCT06033326)
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Lille
Psychoses, Affective Disorder
Patient-controlled Admissions in Inpatient Mental Health Services
Patient-controlled admissions are short self-referred inpatient admissions in mental health services without approval by clinicians. The intention is to reduce a high use of inpatient care.
- Trial name
- NCT03609515
- Testing
- Patient-controlled admission
- Volunteers
- 58 people
- Sponsor
- University Hospital, Akershus
Schizophrenia, Schizoaffective Disorder
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT07105111
- Testing
- Valbenazine
- Where
- 19 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia, Bipolar Disorder
Relative Effectiveness of Schizophrenia Therapy Study
The purpose of this study is to validate that SULT4A1-1 status stratification improves responses to atypical antipsychotics in schizophrenia and to extend these findings into bipolar disorder.
- Trial name
- REST (NCT01245348)
- Testing
- SULT4A1-1 genetic test
- Where
- United States
- Volunteers
- 1,110 people
- Sponsor
- Medco Health Solutions, Inc.
Schizophrenia, Schizoaffective Disorder
Virtual Reality Job Interview Training in Severe Mental Illness
This is a randomized controlled trial to evaluate the community-based effectiveness of virtual reality job interview training (VR-JIT). Northwestern University is partnering with Thresholds Inc.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT03049813
- Testing
- Virtual Reality Job Interview Training, Supported Employment (Services as Usual)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- University of Michigan
Schizophrenia, Major Depressive Disorder
PHARMO Institute Seroquel Safety Study
The purpose of this observational study is to study specific outcomes of interest in users of quetiapine compared with all other atypical antipsychotics and specifically olanzapine and risperidone.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar Disorder, Generalized Anxiety Disorder
- Trial name
- PHARMO II (NCT01342120)
- Volunteers
- 18,325 people
- Sponsor
- AstraZeneca
Schizophrenia, Bipolar Disorder
A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders
The purpose of this study is to evaluate the safety and tolerability of oral ziprasidone in children and teens with psychotic disorders
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT00650611
- Testing
- Ziprasidone
- Where
- 17 sites in United States
- Volunteers
- 63 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.